Christian Kurzeder
A5103276402- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Breast Cancer Treatment Studies
- Intraperitoneal and Appendiceal Malignancies
- Renal cell carcinoma treatment
- Breast Implant and Reconstruction
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Uterine Myomas and Treatments
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Cancer Mechanisms and Therapy
- PARP inhibition in cancer therapy
- Advanced Breast Cancer Therapies
- Reconstructive Surgery and Microvascular Techniques
- Mathematical Biology Tumor Growth
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
- Cervical Cancer and HPV Research
- Multiple and Secondary Primary Cancers
- Monoclonal and Polyclonal Antibodies Research
- Neutropenia and Cancer Infections
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Cancer Diagnosis and Treatment
University Hospital of Basel
2017-2025
University of Basel
2017-2025
Breast Center
2017-2024
Kliniken Essen-Mitte
2011-2019
Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe
2016-2019
Universität Ulm
2004-2019
Universitäts Frauenklinik
2006-2019
AGO Austria
2019
Universität Innsbruck
2019
University Medical Center Hamburg-Eppendorf
2010-2016
Angiogenesis plays a role in the biology of ovarian cancer. We examined effect bevacizumab, vascular endothelial growth factor inhibitor, on survival women with this disease.
Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived (PDGFR) -α/-β, and c-Kit. Preclinical clinical studies support VEGFR PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role pazopanib maintenance therapy in patients with whose disease did not progress during first-line chemotherapy.Nine hundred forty histologically confirmed ovary, fallopian tube, or peritoneum, International Federation...
Purpose: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) resection at first surgery, (2) good performance status, and (3) absence ascites. II planned to verify this hypothesis prospectively multicenter setting. Methods: Participating centers enrolled all consecutive patients with platinum-sensitive or second relapse. applied patients, but free decide on therapy. All further...
Importance Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from positive to negative neoadjuvant chemotherapy are sparse. Additionally, the best surgical staging technique this scenario is unknown. Objective To investigate sentinel biopsy (SLNB) dual-tracer mapping or targeted (TAD), which combines SLNB localization and retrieval clipped node. Design, Setting, Participants In multicenter retrospective cohort...
Abstract The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety cancer types. In breast cancer, preclinical studies showed that inhibitors the Na + /K ATPase suppress CTC block metastasis. Here we conducted prospective, open-label, proof-of-concept study women metastatic where primary objective was to determine whether treatment inhibitor digoxin could reduce mean cluster size. An analysis nine patients treated daily...
To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer first clinical remission.Patients International Federation of Gynecology Obstetrics stage III to IV complete remission after primary surgery platinum- taxane-based chemotherapy were randomly assigned at a ratio 2:1 phase III, double-blind, placebo-controlled, multicenter study. Abagovomab 2 mg or placebo was administered as 1-mL suspension once every...
Abstract Circulating tumour cell (CTC) clusters have been proposed to be major players in the metastatic spread of breast cancer, particularly during advanced disease stages. Yet, it is unclear whether or not they manifest early as their occurrence patients with metastasis-free primary has thoroughly evaluated. In this study, exploiting nanostructured titanium oxide-coated slides for shear-free CTC identification, we detect clustered CTCs curative setting multiple cancer prior surgical...
One attempt to improve long-term survival in patients with advanced ovarian cancer was thought be the addition of more non-cross-resistant drugs platinum-paclitaxel combination regimens. Gemcitabine among candidates for a third drug.We performed prospective, randomized, phase III, intergroup trial compare carboplatin plus paclitaxel (TC; area under curve [AUC] 5 and 175 mg/m(2), respectively) same additional gemcitabine 800 mg/m(2) on days 1 8 (TCG) previously untreated epithelial cancer. TC...
Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted randomized phase II trial (TOWER [Topotecan Versus Conventional 5-Day Schedule Patients With Platinum-Resistant Ovarian Cancer]) to define the ratio between benefits risks either approach.Patients were randomly assigned two independent two-stage protocols Tw (4 mg/m(2)/wk administered...
Purpose The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report results primary efficacy analysis. Patients and Methods Eligible had that progressed during or within 6 months completing four more platinum cycles, centrally tested HER3 expression (concentration ratio ≤ 2.81 by...
Recent technological advances have led to an increase in the production and availability of single-cell data. The ability integrate a set multi-technology measurements would allow identification biologically or clinically meaningful observations through unification perspectives afforded by each technology. In most cases, however, profiling technologies consume used cells thus pairwise correspondences between datasets are lost. Due sheer size can acquire, scalable algorithms that able...
Importance The role of axillary lymph node dissection (ALND) to determine nodal burden inform systemic therapy recommendations in patients with clinically (cN)–positive breast cancer (BC) is currently unknown. Objective To address the association ALND cN-positive BC upfront surgery setting and after neoadjuvant chemotherapy (NACT). Design, Setting, Participants This was a prospective, observational, cohort study conducted from August 2018 June 2022. preplanned within phase 3 randomized...
Abstract Background: Data on the oncologic safety of omission axillary lymph node dissection (ALND) in positive (N+) patients who downstage to ypN0 with neoadjuvant chemotherapy (NAC) is sparse. Additionally, there no consensus which staging procedure should be used this setting, sentinel biopsy (SLNB) alone or combination localization and retrieval clipped node, also known as targeted (TAD). Whether reduction false negative rate observed TAD translates into a significant recurrence unknown....
LBA5501 Background: Paclitaxel or pegylated liposomal doxorubicin (PLD) in combination with bevacizumab (bev) are standard treatment options patients relapsed ovarian cancer not candidates for platinum, but responses usually short-lived. Recently, two trials have reported a numerical non-significant advantage from the addition of atezolizumab (atezo) to chemo plus bev recurrent setting (ATALANTE, Kurtz JE et al., J Clin Oncol & NRG GY009, O'Cearbhaill al, IGCS 2023). AGO-OVAR 2.29...